Functional genomics: Identifying drug targets for parasitic diseases

Trends in Parasitology

Volumn 19, Issue 11, 2003, Pages 538-543

  Cowman, Alan F ^a   Crabb, Brendan S ^a  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4,6 DIAMINO 1,2 DIHYDRO 2,2 DIMETHYL 1 [3 (2,4,5 TRICHLOROPHENOXY)PROPOXY] 1,3,5 TRIAZINE; AGENARASE; AMPRENAVIR; ANTIINFECTIVE AGENT; ANTIPARASITIC AGENT; CHLORPROGUANIL; DAPSONE; DOXYCYCLINE; FOLIC ACID ANTAGONIST; FOSMIDOMYCIN; INDINAVIR; ISONIAZID; LINCOSAMIDE DERIVATIVE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MACROLIDE; NELFINAVIR; THIOLACTOMYCIN; VACCINE;

BIOAVAILABILITY; BIOINFORMATICS; DRUG IDENTIFICATION; DRUG TARGETING; GENE SEQUENCE; GENETIC ANALYSIS; GENOMICS; NONHUMAN; PARASITOSIS; PLASMODIUM FALCIPARUM; REVIEW; SCREENING TEST;

PLASMODIUM FALCIPARUM; PROTOZOA;

EID: 0142165164     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2003.09.006     Document Type: Review

References (41)

1. Gardner M.J., et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature. 419:2002;498-511.
2. Foster J.M., Johnston D.A. Helminth genomics: from gene discovery to genome sequencing. Trends Parasitol. 18:2002;241-242.
3. Ralph S.A., et al. The apicoplast as an antimalarial drug target. Drug Resist. Updat. 4:2001;145-151.
4. Gull K. The cell biology of parasitism in Trypanosoma brucei: insights and drug targets from genomic approaches? Curr. Pharm. Des. 8:2002;241-256.
5. DiMasi J.A., et al. Research and development costs for new drugs by therapeutic category. A study of the US pharmaceutical industry. Pharmacoeconomics. 7:1995;152-169.
6. McFadden G.I., Roos D.S. Apicomplexan plastids as drug targets. Trends Microbiol. 7:1999;328-333.
7. Foth B.J., et al. Dissecting apicoplast targeting in the malaria parasite Plasmodium falciparum. Science. 299:2003;705-708.
8. Roos D.S., et al. Origin, targeting, and function of the apicomplexan plastid. Curr. Opin. Microbiol. 2:1999;426-432.
9. Waller R.F., et al. A type II pathway for fatty acid biosynthesis presents drug targets in Plasmodium falciparum. Antimicrob. Agents Chemother. 47:2003;297-301.
10. Jomaa H., et al. Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. Science. 285:1999;1573-1576.
11. Lell B., et al. Fosmidomycin, a novel chemotherapeutic agent for malaria. Antimicrob. Agents Chemother. 47:2003;735-738.
12. Missinou M.A., et al. Fosmidomycin for malaria. Lancet. 360:2002;1941-1942.
13. Wu Y., et al. Data-mining approaches reveal hidden families of proteases in the genome of malaria parasite. Genome Res. 13:2003;601-616.
14. Rosenthal P.J., et al. Cysteine proteases of malaria parasites: targets for chemotherapy. Curr. Pharm. Des. 8:2002;1659-1672.
15. Markland W., et al. Structural and kinetic analyses of the protease from an amprenavir-resistant human immunodeficiency virus type 1 mutant rendered resistant to saquinavir and resensitized to amprenavir. J. Virol. 74:2000;7636-7641.
16. Strausberg R.L., Schreiber S.L. From knowing to controlling: a path from genomics to drugs using small molecule probes. Science. 300:2003;294-295.
17. Greenbaum D.C., et al. A role for the protease falcipain 1 in host cell invasion by the human malaria parasite. Science. 298:2002;2002-2006.
18. Patankar S., et al. Serial analysis of gene expression in Plasmodium falciparum reveals the global expression profile of erythrocytic stages and the presence of anti-sense transcripts in the malarial parasite. Mol. Biol. Cell. 12:2001;3114-3125.
19. Aebersold R., Mann M. Mass spectrometry-based proteomics. Nature. 422:2003;198-207.
20. Wilson M., et al. Exploring drug-induced alterations in gene expression in Mycobacterium tuberculosis by microarray hybridization. Proc. Natl. Acad. Sci. U. S. A. 96:1999;12833-12838.
21. Rathod P.K., et al. DNA microarrays for malaria. Trends Parasitol. 18:2002;39-45.
22. Bozdech Z., et al. Expression profiling of the schizont and trophozoite stages of Plasmodium falciparum with a long-oligonucleotide microarray. Genome Biol. 4:2003;R9.
23. Nirmalan N., et al. Transcriptional analysis of genes encoding enzymes of the folate pathway in the human malaria parasite Plasmodium falciparum. Mol. Microbiol. 46:2002;179-190.
24. Barry C.E. III, Schroeder B.G. DNA microarrays: translational tools for understanding the biology of Mycobacterium tuberculosis. Trends Microbiol. 209:2000;209-210.
25. Van Duin M., et al. Genomics in target and drug discovery. Biochem. Soc. Trans. 31:2003;429-432.
26. Miller S.K., et al. A subset of Plasmodium falciparum SERA genes are expressed and appear to play an important role in the erythrocytic cycle. J. Biol. Chem. 277:2002;47524-47532.
27. Beverley S.M. Protozomics: trypanosomatid parasite genetics comes of age. Nat. Rev. Genet. 4:2003;11-19.
28. Morris J.C., et al. Glycolysis modulates trypanosome glycoprotein expression as revealed by an RNAi library. EMBO J. 21:2002;4429-4438.
29. McRobert L., McConkey G.A. RNA interference (RNAi) inhibits growth of Plasmodium falciparum. Mol. Biochem. Parasitol. 119:2002;273-278.
30. Malhotra P., et al. Double-stranded RNA-mediated gene silencing of cysteine proteases (falcipain-1 and -2) of Plasmodium falciparum. Mol. Microbiol. 45:2002;1245-1254.
31. Crabb B.S. Transfection technology and the study of drug resistance in the malaria parasite Plasmodium falciparum. Drug Resist. Updat. 5:2002;126-130.
32. Higazi T.B., et al. Brugia malayi: transient transfection by microinjection and particle bombardment. Exp. Parasitol. 100:2002;95-102.
33. Brooks D.R., Isaac R.E. Functional genomics of parasitic worms: the dawn of a new era. Parasitol. Int. 51:2002;319-325.
34. Trouiller P., et al. Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet. 359:2002;2188-2194.
35. Warhurst D.C. Resistance to antifolates in Plasmodium falciparum, the causative agent of tropical malaria. Sci. Prog. 85:2002;89-111.
36. Fairlamb A.H., Cerami A. Metabolism and functions of trypanothione in the Kinetoplastida. Annu. Rev. Microbiol. 46:1992;695-729.
37. Reckenfelderbaumer N., et al. Identification and functional characterization of thioredoxin from Trypanosoma brucei brucei. J. Biol. Chem. 275:2000;7547-7552.
38. Dumas C., et al. Disruption of the trypanothione reductase gene of Leishmania decreases its ability to survive oxidative stress in macrophages. EMBO J. 16:1997;2590-2598.
39. Krieger S., et al. Trypanosomes lacking trypanothione reductase are avirulent and show increased sensitivity to oxidative stress. Mol. Microbiol. 35:2000;542-552.
40. Ariyanayagam, M.R. et al. Bis(glutathionyl)spermine and other novel trypanothione analogues in Trypanosome cruzi. J. Biol. Chem. (in press).
41. Aoki S., et al. Serine repeat antigen (SERA5) is predominantly expressed among the SERA multigene family of Plasmodium falciparum, and the acquired antibody titers correlate with serum inhibition of the parasite growth. J. Biol. Chem. 277:2002;47533-47540.